Martin E. Sanders, MD
Founder, President, & CEO
Dr. Sanders has had a long career in biomedical basic research, biopharmaceutical product development, executive management of life science companies, and venture capital investing in early stage life science companies. He also serves as a founding member of the advisory board for the University of Chicago Polsky Center Innovation Fund.
Dr. Sanders is a graduate of the University of Chicago Pritzker School of Medicine. He completed post-graduate training in Internal Medicine at Washington University School of Medicine, post-doctoral training in Allergy and Clinical Immunology at the National Institute of Health, and in Rheumatology at the Johns Hopkins School of Medicine. He is board certified in Internal Medicine, Allergy and Clinical Immunology, and Rheumatology.
Laurel Therapeutics, Inc., is developing patented anti-angiogenic and vascular hyperpermeability inhibiting peptides which block microtubule end binding protein 3 interaction with inositol 3,4,5-triphosphate receptor Type 3. Preclinical studies have demonstrated that these peptides have potential for being safe and effective for the treatment of diverse diseases involving pathologic angiogenesis and/or vascular hyperpermeability.
The company’s highest priority is to develop EBIN (End Binding Inhibitor), a myristoylated seven amino acid cell-penetrant peptide which inhibits VEGF-induced angiogenesis and vascular permeability, as a topically administered eye drop formulation for treatment of age-related macular degeneration, diabetic retinopathy, and other angiogenic eye diseases.
EBIN and related peptides also have demonstrated activity in multiple preclinical models of systemic vascular hyperpermeability, including bacteremia, endotoxemia, acute lung injury, allergic anaphylaxis, histamine-induced hypotension; and in cancer.